Trials / Unknown

UnknownNCT03411967

Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC

Clinical Study of Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC After Failure of Platinum-based Double-drug Therapy

Status: Unknown
Phase: Phase 2
Study type: Interventional
Enrollment: 20 (estimated)

Sponsor: Zigong No.1 Peoples Hospital · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

In order to explore a new treatment strategy for patients with failed NSCLC platinum-containing double-drug therapy, this study was to investigate the clinical efficacy of apatinib in combination with docetaxel for patients with advanced NSCLC after failure of platinum-based regime

Conditions

Lung Cancer

Interventions

Type	Name	Description
DRUG	Apatinib	apatinib mesylate tablets 500mg, po, qd, continued until the next cycle, taking on an empty stomach (daily taken at the same time), every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment, apatinib has been taken until the disease progresses, intolerable toxicity.
DRUG	Docetaxel	Docetaxel, 60 mg / m2, d1, iv ,every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment

Timeline

Start date: 2018-02-01
Primary completion: 2020-12-01
Completion: 2021-12-01
First posted: 2018-01-26
Last updated: 2018-01-26

Source: ClinicalTrials.gov record NCT03411967. Inclusion in this directory is not an endorsement.